公开(公告)号：US20150274721A1

公开(公告)日：2015-10-01

申请号：US14670746

申请日：2015-03-27

Applicant: Pfizer Inc.

Inventor： Martin Youngjin Pettersson ,  Christopher William am Ende ,  John Michael Humphrey ,  Douglas Scott Johnson ,  Gregory Wayne Kauffman ,  Danica Antonia Rankic ,  Antonia Friederike Stepan ,  Patrick Robert Verhoest

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I wherein X, R1, R2a, R2b, R4a, R4b, R5a, R5b, R6, R7, y and z are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract translation: 公开了化合物的化合物和药学上可接受的盐，其中化合物具有式I的结构，其中X，R1，R2a，R2b，R4a，R4b，R5a，R5b，R6，R7，y和z如本说明书中所定义 。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。

公开(公告)号：US20220062232A1

公开(公告)日：2022-03-03

申请号：US17395139

申请日：2021-08-05

Applicant: Pfizer Inc.

Inventor： Dafydd Rhys Owen ,  Martin Youngjin Pettersson ,  Matthew Richard Reese ,  Matthew Forrest Sammons ,  Jamison Bryce Tuttle ,  Patrick Robert Verhoest ,  Liuqing Wei ,  Qingyi Yang ,  Xiaojing Yang

IPC: A61K31/403 ,  C07D403/12 ,  A61K31/427 ,  A61P31/14

Abstract: The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.

公开(公告)号：US20200331909A1

公开(公告)日：2020-10-22

申请号：US16849329

申请日：2020-04-15

Applicant: Pfizer Inc.

Inventor： Samit Kumar Bhattacharya ,  Douglas Carl Behenna ,  Kimberly O. Cameron ,  Ping Chen ,  John M. Curto ,  Kevin Daniel Freeman-Cook ,  Mehran Jalaie ,  Robert Steven Kania ,  Yajing Lian ,  Sajiv Krishnan Nair ,  Cynthia Louise Palmer ,  Martin Youngjin Pettersson ,  Eugene Yuanjin Rui ,  Matthew Sammons ,  Qingyi Yang ,  Liying Zhang

IPC: C07D471/04 ,  A61P9/12

Abstract: This invention relates to compounds of general Formula I in which A, R1, R2, R3 and R4 are as defined herein, and the pharmaceutically acceptable salts thereof; to pharmaceutical compositions comprising such compounds and salts; to methods of using such compounds, salts and compositions for treating pulmonary hypertension and related diseases, like pulmonary arterial hypertension; to methods of using such compounds, salts and compositions for treating abnormal cell growth, such as cancer; and to processes to make such compounds, salts and compositions.

公开(公告)号：US20170073343A1

公开(公告)日：2017-03-16

申请号：US15262112

申请日：2016-09-12

Applicant: Pfizer Inc.

Inventor： Paul Galatsis ,  Jaclyn Louise Henderson ,  Bethany Lyn Kormos ,  Ravi G. Kurumbail ,  Matthew Richard Reese ,  Antonia Friederike Stepan ,  Patrick Robert Verhoest ,  Travis T. Wager ,  Martin Youngjin Pettersson ,  Michelle Renee Garnsey

IPC: C07D471/04 ,  C07D471/14 ,  C07D519/00

CPC classification number: A61K31/435 ,  A61K31/4745 ,  C07D215/38 ,  C07D215/42 ,  C07D471/04 ,  C07D471/14 ,  C07D519/00

Abstract: The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R1, R1a, R1b, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

Abstract translation: 其中R1，R1a，R1b，R2，R4，R5，R6，X和Z如说明书中所定义。 本发明还涉及包含式（I）化合物的药物组合物，以及该化合物在治疗与LRRK2相关的疾病中的应用，例如包括帕金森病或阿尔茨海默氏病，癌症，克罗恩病或麻风病的神经变性疾病。

公开(公告)号：US09067934B2

公开(公告)日：2015-06-30

申请号：US14053924

申请日：2013-10-15

Applicant: Pfizer Inc.

Inventor： Martin Youngjin Pettersson ,  Douglas Scott Johnson ,  Chakrapani Subramanyam ,  Christopher John O'Donnell ,  Christopher William am Ende ,  Benjamin Adam Fish ,  Michael Eric Green ,  Patrick Bradley Mullins ,  Cory Michael Stiff ,  Tuan Phong Tran ,  Thayalan Navaratnam

IPC: C07D471/04 ,  C07D401/04 ,  A61K31/4985 ,  A61K31/695 ,  A61K45/06 ,  C07D491/048 ,  C07F7/08

CPC classification number: C07D471/04 ,  A61K31/4985 ,  A61K31/695 ,  A61K45/06 ,  C07D401/04 ,  C07D491/048 ,  C07F7/0812

Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined herein. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract translation: 公开了化合物的化合物和药学上可接受的盐，其中所述化合物具有如本文所定义的式I的结构。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。

公开(公告)号：US20230120707A1

公开(公告)日：2023-04-20

申请号：US17906132

申请日：2021-03-31

Applicant: Pfizer Inc.

Inventor： Robert Steven Kania ,  Dafydd Rhys Owen ,  Martin Youngjin Pettersson ,  Matthew Forrest Sammons ,  Jamison Bryce Tuttle

IPC: C07D403/14 ,  A61K9/20 ,  A61K9/00

Abstract: The invention relates to compounds of formula I wherein R1 and R2 are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compound

公开(公告)号：US11351149B2

公开(公告)日：2022-06-07

申请号：US17395139

申请日：2021-08-05

Applicant: Pfizer Inc.

Inventor： Dafydd Rhys Owen ,  Martin Youngjin Pettersson ,  Matthew Richard Reese ,  Matthew Forrest Sammons ,  Jamison Bryce Tuttle ,  Patrick Robert Verhoest ,  Liuqing Wei ,  Qingyi Yang ,  Xiaojing Yang

IPC: C07D403/12 ,  A61K31/403 ,  A61P31/14 ,  A61K31/427

Abstract: The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.

公开(公告)号：US11203594B2

公开(公告)日：2021-12-21

申请号：US16849329

申请日：2020-04-15

Applicant: Pfizer Inc.

Inventor： Samit Kumar Bhattacharya ,  Douglas Carl Behenna ,  Kimberly O. Cameron ,  Ping Chen ,  John M. Curto ,  Kevin Daniel Freeman-Cook ,  Mehran Jalaie ,  Robert Steven Kania ,  Yajing Lian ,  Sajiv Krishnan Nair ,  Cynthia Louise Palmer ,  Martin Youngjin Pettersson ,  Eugene Yuanjin Rui ,  Matthew Sammons ,  Qingyi Yang ,  Liying Zhang

IPC: C07D471/04 ,  A61P9/12

Abstract: This invention relates to compounds of general Formula I in which A, R1, R2, R3 and R4 are as defined herein, and the pharmaceutically acceptable salts thereof; to pharmaceutical compositions comprising such compounds and salts; to methods of using such compounds, salts and compositions for treating pulmonary hypertension and related diseases, like pulmonary arterial hypertension; to methods of using such compounds, salts and compositions for treating abnormal cell growth, such as cancer; and to processes to make such compounds, salts and compositions.

公开(公告)号：US20160229847A1

公开(公告)日：2016-08-11

申请号：US15022313

申请日：2014-09-22

Applicant: PFIZER INC.

Inventor： Martin Youngjin Pettersson ,  Christopher William am Ende ,  Michael Eric Green ,  Douglas Scott Johnson ,  Gregory Wayne Kauffman ,  Christopher William O'Donnell ,  Nandini Chaturbhai Patel ,  Antonia Friederike Stepan ,  Cory Michael Stiff ,  Chakrapani Subramanyam ,  Tuan Phong Tran ,  Patrick Robert Verhoest

IPC: C07D471/04 ,  C07D498/04

CPC classification number: C07D471/04 ,  C07D498/04

Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula II as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract translation: 公开了化合物的化合物和药学上可接受的盐，其中所述化合物具有如说明书中定义的式II的结构。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。

公开(公告)号：US20140045790A1

公开(公告)日：2014-02-13

申请号：US14053924

申请日：2013-10-15

Applicant: Pfizer Inc.

Inventor： Martin Youngjin Pettersson ,  Douglas Scott Johnson ,  Chakrapani Subramanyam ,  Christopher John O'Donnell ,  Christopher William am Ende ,  Benjamin Adam Fish ,  Michael Eric Green ,  Patrick Bradley Mullins ,  Cory Michael Stiff ,  Tuan Phong Tran ,  Thayalan Navaratnam

IPC: C07D471/04 ,  C07D401/04 ,  C07F7/08 ,  C07D491/048 ,  A61K31/695 ,  A61K31/4985 ,  A61K45/06

CPC classification number: C07D471/04 ,  A61K31/4985 ,  A61K31/695 ,  A61K45/06 ,  C07D401/04 ,  C07D491/048 ,  C07F7/0812

Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined herein. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract translation: 公开了化合物的化合物和药学上可接受的盐，其中所述化合物具有如本文所定义的式I的结构。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。